Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Leukemia
|
June 26, 2014
CSNK1α1 mediates malignant plasma cell survival
Y Hu, W Song, D Cirstea, et al.
Blood Cancer Journal
|
April 22, 2026
Validation and refinement of the new Consensus Genomic Staging (CGS) of high-risk multiple myeloma (HRMM) in relapsed and refractory patients treated with BCMA CAR-T
Joshua N Gustine, Narsis Attar, Benjamin R Puliafito, et al.
Leukemia
|
February 19, 2013
Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy
T Scullen, L Santo, S Vallet, et al.
Leukemia
|
March 16, 2011
A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function
S Vallet, S Pozzi, K Patel, et al.
Leukemia
|
April 17, 2009
Ascorbic acid inhibits antitumor activity of bortezomib in vivo
G Perrone, T Hideshima, H Ikeda, et al.
Blood Advances
|
March 14, 2025
Early daratumumab therapy improves renal outcomes in newly diagnosed myeloma patients admitted with kidney injury
E Bridget Kim, Jack E Malespini, Matthew Lei, et al.
Blood Advances
|
July 21, 2025
IVIG prophylaxis should be initiated following bispecific antibody therapy in multiple myeloma regardless of IgG levels
Rahul Banerjee, Meera Mohan, Kai Rejeski, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
January 15, 2016
Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease
Homare Eda, Loredana Santo, Marc N Wein, et al.
Leukemia
|
June 29, 2013
Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs
D Cirstea, T Hideshima, L Santo, et al.
Leukemia
|
February 13, 2014
A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity
H Eda, L Santo, D D Cirstea, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Leukemia
|
June 26, 2014
CSNK1α1 mediates malignant plasma cell survival
Y Hu, W Song, D Cirstea, et al.
Blood Cancer Journal
|
April 22, 2026
Validation and refinement of the new Consensus Genomic Staging (CGS) of high-risk multiple myeloma (HRMM) in relapsed and refractory patients treated with BCMA CAR-T
Joshua N Gustine, Narsis Attar, Benjamin R Puliafito, et al.
Leukemia
|
February 19, 2013
Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy
T Scullen, L Santo, S Vallet, et al.
Leukemia
|
March 16, 2011
A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function
S Vallet, S Pozzi, K Patel, et al.
Leukemia
|
April 17, 2009
Ascorbic acid inhibits antitumor activity of bortezomib in vivo
G Perrone, T Hideshima, H Ikeda, et al.
Blood Advances
|
March 14, 2025
Early daratumumab therapy improves renal outcomes in newly diagnosed myeloma patients admitted with kidney injury
E Bridget Kim, Jack E Malespini, Matthew Lei, et al.
Blood Advances
|
July 21, 2025
IVIG prophylaxis should be initiated following bispecific antibody therapy in multiple myeloma regardless of IgG levels
Rahul Banerjee, Meera Mohan, Kai Rejeski, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
January 15, 2016
Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease
Homare Eda, Loredana Santo, Marc N Wein, et al.
Leukemia
|
June 29, 2013
Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs
D Cirstea, T Hideshima, L Santo, et al.
Leukemia
|
February 13, 2014
A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity
H Eda, L Santo, D D Cirstea, et al.
Page
of 2